<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Pulmonary disease induced by cardiovascular drugs</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Pulmonary disease induced by cardiovascular drugs</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Pulmonary disease induced by cardiovascular drugs</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Edward D Chan, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Talmadge E King, Jr, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Kevin R Flaherty, MD, MS</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Paul Dieffenbach, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Aug 22, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>A number of cardiovascular drugs have the potential to cause respiratory impairment, although diffuse parenchymal lung disease is quite rare (<a class="graphic graphic_table graphicRef54967 graphicRef69778" href="/z/d/graphic/54967.html" rel="external">table 1A-B</a>). Several different respiratory adverse effects have been identified: upper airway angioedema or hematoma, bronchoconstriction, cough, interstitial pneumonitis, organizing pneumonia, eosinophilic pneumonia, drug-induced lupus, acute respiratory distress syndrome, diffuse alveolar hemorrhage, pleuritis, pleural effusion, methemoglobinemia, and solitary lung mass. </p><p>This topic review will provide an overview of the lung diseases induced by various cardiovascular drugs. The clinical manifestations, diagnosis, and management of pulmonary toxicity due to <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">amiodarone</a> and an approach to the diagnosis of interstitial lung disease are discussed separately.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/4364.html" rel="external">"Amiodarone pulmonary toxicity"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/4310.html" rel="external">"Approach to the adult with interstitial lung disease: Clinical evaluation"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/4358.html" rel="external">"Approach to the adult with interstitial lung disease: Diagnostic testing"</a>.)</p><p></p><p class="headingAnchor" id="H982217145"><span class="h1">AMIODARONE</span><span class="headingEndMark"> — </span>Pulmonary toxicity is a well-known adverse effect of the antiarrhythmic agent <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">amiodarone</a>. Several forms of pulmonary disease have been described, including interstitial pneumonitis, organizing pneumonia, acute respiratory distress syndrome (ARDS), diffuse alveolar hemorrhage (DAH), eosinophilic pneumonia, pulmonary nodules, solitary masses, and also (rarely) pleural effusion. The clinical presentation, pathogenesis, diagnosis, and treatment of amiodarone pulmonary toxicity are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/4364.html" rel="external">"Amiodarone pulmonary toxicity"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">ANGIOTENSIN-CONVERTING ENZYME INHIBITORS</span><span class="headingEndMark"> — </span>Angiotensin-converting enzyme (ACE) inhibitors are associated with cough, angioedema, and, rarely, pneumonitis.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cough</strong> – All of the ACE inhibitors can induce a dry, persistent, and often nocturnal cough (in 5 to 20 percent of patients). The cough may develop within hours of the first dose or weeks to months later. It is more common in women, non-smokers, and persons of Chinese origin. The cough typically resolves one to four weeks after discontinuation of the ACE inhibitor but in a subgroup of coughers, resolution may take several months [<a href="#rid1">1</a>]. One important caveat is that cough may be a symptom of heart failure, and a thorough history and physical examination are needed to ascertain whether the cough is truly related to the ACE inhibitor therapy. (See  <a class="medical medical_review" href="/z/d/html/3816.html" rel="external">"Major side effects of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers"</a> and  <a class="medical medical_review" href="/z/d/html/1460.html" rel="external">"Causes and epidemiology of subacute and chronic cough in adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Angioedema</strong> – Angioedema, particularly of the oropharynx and larynx, complicates ACE inhibitor therapy in approximately 0.1 to 0.7 percent of recipients. ACE inhibitor-induced angioedema is mediated by excess bradykinin, which builds up due to both lower ACE activity and reduced angiotensin II production. Since ACE inhibitor-associated angioedema typically causes swelling of the mouth, lips, tongue, larynx, pharynx, and subglottic tissues, upper airway compromise may be the presenting sign. Pruritus and urticaria are typically absent. Unlike classical hereditary angioedema, C1 inhibitor level and function and thus the C4 levels are normal in ACE inhibitor-associated angioedema. (See  <a class="medical medical_review" href="/z/d/html/8099.html" rel="external">"An overview of angioedema: Pathogenesis and causes", section on 'ACE inhibitors'</a> and  <a class="medical medical_review" href="/z/d/html/16380.html" rel="external">"ACE inhibitor-induced angioedema", section on 'Pathophysiology'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Interstitial pneumonitis</strong> – <a class="drug drug_general" data-topicid="9196" href="/z/d/drug information/9196.html" rel="external">Captopril</a> and <a class="drug drug_general" data-topicid="9758" href="/z/d/drug information/9758.html" rel="external">perindopril</a> have rarely been associated with the development of diffuse interstitial pneumonitis. An eosinophilic pneumonia was found in most cases, but an acute hypersensitivity pneumonitis with lymphocytic infiltration has been described [<a href="#rid2">2-6</a>]. The radiographic appearance is nonspecific, with bilateral patchy ground glass or consolidative opacities being the most frequent finding. The diagnosis is usually made on the basis of peripheral blood or bronchoalveolar lavage eosinophilia, exclusion of infection, and/or response to empiric drug discontinuation. Occasionally, a lung biopsy is needed. Therapy consists of drug withdrawal; occasionally systemic glucocorticoids have been used for patients with more severe respiratory impairment [<a href="#rid5">5,6</a>]. (See  <a class="medical medical_review" href="/z/d/html/4358.html" rel="external">"Approach to the adult with interstitial lung disease: Diagnostic testing"</a>.)</p><p></p><p class="headingAnchor" id="H982217495"><span class="h1">ANGIOTENSIN RECEPTOR BLOCKERS</span><span class="headingEndMark"> — </span>The incidence of cough appears not to be increased with use of the angiotensin receptor blockers (ARB). Angiotensin receptor blockers (ARB) are associated with a low rate of angioedema (0.1 to 0.2 percent in large trials). However, the cross-reactivity with angiotensin-converting enzyme (ACE) inhibitors is difficult to ascertain because of the phenomenon that patients with ACE inhibitor induced angioedema may continue to have episodes for weeks to months following discontinuation of the ACE inhibitor, which may overlap with initiation of the ARB. In a systematic review and meta-analysis of 11 randomized trials evaluating ARB in patients intolerant to ACE inhibitors, ARB had cough and angioedema incidences similar to placebo [<a href="#rid7">7</a>]. </p><p class="headingAnchor" id="H982217800"><span class="h1">ANTIPLATELET (NON-ASPIRIN), ANTICOAGULANT, AND THROMBOLYTIC MEDICATIONS</span><span class="headingEndMark"> — </span>Use of anti-platelet medications (glycoprotein IIB/IIIA antagonists) [<a href="#rid8">8-17</a>], anticoagulants (vitamin K antagonists, direct thrombin inhibitor, factor Xa inhibitor) [<a href="#rid18">18-22</a>], and thrombolytic agents [<a href="#rid23">23-25</a>] in patients with coronary artery disease has been associated with bland diffuse alveolar hemorrhage (DAH). DAH has a similar presentation to pulmonary edema, so a high index of suspicion is needed, particularly when a patient with presumed pulmonary edema does not respond promptly to diuresis. The diagnosis and management of DAH are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/4341.html" rel="external">"The diffuse alveolar hemorrhage syndromes"</a>.)</p><p>Rarely, spontaneous pharyngeal and laryngeal hematomas associated with <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">warfarin</a> anticoagulation have caused airway obstruction [<a href="#rid26">26-28</a>].</p><p>A few cases have been reported of interstitial pneumonitis due to <a class="drug drug_general" data-topicid="9996" href="/z/d/drug information/9996.html" rel="external">ticlopidine</a> and <a class="drug drug_general" data-topicid="8921" href="/z/d/drug information/8921.html" rel="external">clopidogrel</a> [<a href="#rid29">29-32</a>].</p><p class="headingAnchor" id="H1148600663"><span class="h1">ASPIRIN</span><span class="headingEndMark"> — </span>Patients with aspirin-exacerbated respiratory disease (AERD), also known as Samter's triad (asthma, nasal polyposis, and acute bronchoconstriction secondary to <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> ingestion), can experience acute bronchoconstriction after ingestion of aspirin. Some patients tolerate 81 mg of aspirin but develop symptoms at 162 or 325 mg. If patients experience dyspnea within three hours of starting or increasing aspirin dosage, AERD may be the cause. Most patients will experience a combination of nasal congestion, rhinorrhea, wheezing, and dyspnea. Additional symptoms may include facial flushing/erythema, laryngospasm, abdominal cramps, epigastric pain, and hypotension. Bronchoconstriction is typically reversible with an inhaled bronchodilator, which should be given promptly. Aspirin desensitization is an option for patients with AERD who require aspirin therapy. In addition, such protocolized desensitization has been shown to improve nasal-sinus and asthma symptoms in those with suboptimal control of their asthma [<a href="#rid33">33</a>]. When undertaking desensitization, premedication with a leukotriene-modifying agent such as <a class="drug drug_general" data-topicid="9539" href="/z/d/drug information/9539.html" rel="external">montelukast</a> is recommended. The protocol for aspirin desensitization is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/520.html" rel="external">"Aspirin-exacerbated respiratory disease"</a> and  <a class="medical medical_review" href="/z/d/html/15539.html" rel="external">"Aspirin-exacerbated respiratory disease: NSAID challenge and desensitization", section on 'Challenge protocols and procedures'</a>.)</p><p class="headingAnchor" id="H3"><span class="h1">BETA-ADRENERGIC RECEPTOR BLOCKERS</span><span class="headingEndMark"> — </span>Beta-adrenergic receptor blockers ("beta-blockers") can exacerbate diseases of the airways (eg, chronic obstructive lung disease [COPD] and asthma) and the pulmonary vasculature (eg, portopulmonary hypertension). However, only rarely have they been associated with pleural or pulmonary parenchymal diseases, such as drug-induced lupus and interstitial pneumonitis.</p><p class="headingAnchor" id="H4"><span class="h2">Asthma and COPD</span><span class="headingEndMark"> — </span>Beta-blockers are commonly used to treat hypertension, heart failure, and symptomatic coronary artery disease. However, beta-blocking medications that act on beta2 receptors can also cause bronchoconstriction. Since beta-adrenergic receptors of large and small airway smooth muscle are primarily the beta2 subtype, nonselective beta1/beta2-blockers (eg, <a class="drug drug_general" data-topicid="9829" href="/z/d/drug information/9829.html" rel="external">propranolol</a>) are more likely to cause bronchoconstriction in susceptible individuals [<a href="#rid34">34</a>]. In contrast, selective beta1-blockers (eg, <a class="drug drug_general" data-topicid="8940" href="/z/d/drug information/8940.html" rel="external">atenolol</a>, <a class="drug drug_general" data-topicid="9645" href="/z/d/drug information/9645.html" rel="external">metoprolol</a>) have a 20-fold greater affinity for beta1 adrenergic receptors than beta2 adrenergic receptors and, therefore, are less likely to induce bronchoconstriction.</p><p>Studies of selective beta1-blockers are reassuring regarding their safety in patients with COPD, including those with a reversible component. In a meta-analysis that examined the effect of cardioselective beta-blockers given as a single dose or for longer duration, the beta1-blockers did not reduce the forced expiratory volume in one second (FEV<sub>1</sub>) or increase respiratory symptoms compared with placebo, and beta1-blocker treatment did not reduce the improvement in FEV<sub>1</sub> following inhaled beta2-agonists [<a href="#rid35">35</a>]. A subgroup analysis revealed no change in results for those participants with severe chronic airways obstruction or for those with a reversible obstructive component.</p><p>The benefits of using beta blockers, like any other drug, must be weighed on a case-by-case basis against the risk of side effects. Nonselective beta-blockers should be avoided in patients with asthma and used with caution in patients with an exacerbation of COPD. The use of selective beta1-blockers in patients who have COPD and a cardiovascular indication is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/1437.html" rel="external">"Management of the patient with COPD and cardiovascular disease", section on 'Treatment of CVD in patients with COPD'</a> and  <a class="medical medical_review" href="/z/d/html/1454.html" rel="external">"Arrhythmias in COPD", section on 'Multifocal atrial tachycardia'</a> and  <a class="medical medical_review" href="/z/d/html/121086.html" rel="external">"Primary pharmacologic therapy for heart failure with reduced ejection fraction", section on 'Beta blocker'</a>.)</p><p class="headingAnchor" id="H8"><span class="h2">Portopulmonary hypertension</span><span class="headingEndMark"> — </span>Beta-blockers are used prophylactically to prevent variceal hemorrhage in patients with cirrhosis complicated by portal hypertension. However, in patients with cirrhosis and portopulmonary hypertension, withdrawal of beta-blockers improved exercise capacity and decreased pulmonary vascular resistance, likely due to heart rate improvements causing increased cardiac output [<a href="#rid36">36</a>]. This indirect evidence suggests that beta-blockers should be used cautiously or avoided in those with symptomatic portopulmonary hypertension [<a href="#rid37">37</a>]. (See  <a class="medical medical_review" href="/z/d/html/1245.html" rel="external">"Primary prevention of bleeding from esophageal varices in patients with cirrhosis", section on 'Preventive strategies'</a> and  <a class="medical medical_review" href="/z/d/html/8266.html" rel="external">"Portopulmonary hypertension"</a> and  <a class="medical medical_review" href="/z/d/html/1252.html" rel="external">"Prevention of recurrent bleeding from esophageal varices in patients with cirrhosis"</a>.)</p><p class="headingAnchor" id="H9"><span class="h2">Drug-induced lupus</span><span class="headingEndMark"> — </span>The development of anti-nuclear antibodies is not uncommon with beta-blocker use, but the incidence of a symptomatic lupus syndrome attributed to a beta-blocker is distinctly less common (<a class="graphic graphic_table graphicRef69467" href="/z/d/graphic/69467.html" rel="external">table 2</a>) [<a href="#rid38">38</a>]. Beta-blocker induced lupus syndrome with pleuritis and pneumonitis has rarely been reported [<a href="#rid39">39</a>]. (See  <a class="medical medical_review" href="/z/d/html/4677.html" rel="external">"Drug-induced lupus"</a>.)</p><p class="headingAnchor" id="H10"><span class="h2">Interstitial lung disease</span><span class="headingEndMark"> — </span>Organizing pneumonia and eosinophilic pneumonia have rarely been reported with beta-blocking agents, such as <a class="drug drug_general" data-topicid="9941" href="/z/d/drug information/9941.html" rel="external">sotalol</a> and <a class="drug drug_general" data-topicid="9233" href="/z/d/drug information/9233.html" rel="external">acebutolol</a> [<a href="#rid40">40-42</a>]. As an example, migratory radiographic opacities were described in a patient on sotalol [<a href="#rid40">40</a>]. On lung biopsy, features of both organizing pneumonia and eosinophilic pneumonia were seen. Partial improvement was noted with addition of systemic glucocorticoids; complete recovery was seen only after sotalol was stopped. (See  <a class="medical medical_review" href="/z/d/html/4332.html" rel="external">"Cryptogenic organizing pneumonia"</a> and  <a class="medical medical_review" href="/z/d/html/4374.html" rel="external">"Idiopathic acute eosinophilic pneumonia"</a>.)</p><p class="headingAnchor" id="H1244527606"><span class="h1">HYDRALAZINE</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8528" href="/z/d/drug information/8528.html" rel="external">Hydralazine</a>, a vasodilating agent, is associated with drug-induced lupus (pleural and pericardial effusions), antineutrophil cytoplasmic antibody positive-pulmonary vasculitis, and diffuse alveolar hemorrhage [<a href="#rid43">43</a>]. (See  <a class="medical medical_review" href="/z/d/html/4677.html" rel="external">"Drug-induced lupus", section on 'Causative drugs'</a> and  <a class="medical medical_review" href="/z/d/html/4677.html" rel="external">"Drug-induced lupus", section on 'Clinical spectrum of drug-induced lupus'</a>.)</p><p class="headingAnchor" id="H1148601604"><span class="h1">MINOXIDIL</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9655" href="/z/d/drug information/9655.html" rel="external">Minoxidil</a> is uncommonly used, mainly to treat recalcitrant hypertension. Fluid retention is a potential adverse effect of the drug. Minoxidil has been associated with the development of pericardial and pleural effusions, which may be exudative [<a href="#rid44">44,45</a>].</p><p class="headingAnchor" id="H982217589"><span class="h1">NITRATES</span><span class="headingEndMark"> — </span>Overdoses of nitrate medications, such as intravenous infusions of <a class="drug drug_general" data-topicid="9706" href="/z/d/drug information/9706.html" rel="external">nitroglycerin</a> or <a class="drug drug_general" data-topicid="9707" href="/z/d/drug information/9707.html" rel="external">nitroprusside</a>, can cause methemoglobinemia. The clinical presentation may include dyspnea, respiratory depression, cyanosis, lethargy, altered consciousness, hypotension, and seizures. Measurement of oxygen saturation by a pulse oximeter may be inaccurate for assessing oxygen saturation as severe methemoglobinemia causes the SpO<sub>2</sub> to trend towards 85 percent and thus may either overestimate or underestimate the true arterial oxygen saturation (SaO<sub>2</sub>) as measured by arterial blood gas analysis [<a href="#rid46">46</a>]. Methemoglobinemia is suspected when the arterial tension of oxygen (PaO<sub>2</sub>) is normal despite clinical cyanosis. The diagnosis is based upon laboratory measurement of methemoglobin. (See  <a class="medical medical_review" href="/z/d/html/7094.html" rel="external">"Methemoglobinemia", section on 'Evaluation and diagnosis (acquired/toxic)'</a>.)</p><p class="headingAnchor" id="H982217700"><span class="h1">PACLITAXEL-ELUTING STENTS</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9735" href="/z/d/drug information/9735.html" rel="external">Paclitaxel</a> is an antineoplastic agent that can cause an interstitial pneumonitis when used to treat cancer. Paclitaxel has also been used to prevent restenosis after placement of coronary artery drug-eluting stents (DES), and case reports have described interstitial pneumonitis associated with these stents [<a href="#rid47">47,48</a>]. The onset of dyspnea, fever, and progressive respiratory insufficiency occurred within days of stent placement. Chest radiographs showed bilateral diffuse opacities. Due to the rarity of these events, the optimal management is not known. The three reported patients succumbed to progressive respiratory failure despite systemic glucocorticoid therapy [<a href="#rid47">47,48</a>]. Paclitaxel DES are no longer used frequently due to the better performance of newer generation DES. (See  <a class="medical medical_review" href="/z/d/html/4355.html" rel="external">"Taxane-induced pulmonary toxicity"</a> and  <a class="medical medical_review" href="/z/d/html/1575.html" rel="external">"Intracoronary stents: Stent types", section on 'Early-generation drug-eluting stents'</a> and  <a class="medical medical_review" href="/z/d/html/1562.html" rel="external">"Periprocedural complications of percutaneous coronary intervention", section on 'Hypersensitivity reactions'</a>.)</p><p class="headingAnchor" id="H12"><span class="h1">PROCAINAMIDE</span><span class="headingEndMark"> — </span>The antiarrhythmic agent <a class="drug drug_general" data-topicid="9813" href="/z/d/drug information/9813.html" rel="external">procainamide</a> is associated with drug-induced lupus, antiphospholipid antibody syndrome, interstitial pneumonitis, and respiratory muscle weakness. A number of extrapulmonary adverse effects are also associated with use of procainamide, including nonspecific systemic symptoms, blood dyscrasias, and cardiac toxicity (see  <a class="medical medical_review" href="/z/d/html/86747.html" rel="external">"Major side effects of class I antiarrhythmic drugs"</a>). Use of procainamide is decreasing with availability of more effective antiarrhythmics such as <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">amiodarone</a>.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Drug-induced lupus</strong> – <a class="drug drug_general" data-topicid="9813" href="/z/d/drug information/9813.html" rel="external">Procainamide</a> can cause a syndrome of drug-induced lupus with protean clinical manifestations, including fever, arthralgia, rashes, myositis, vasculitis, serositis, and Raynaud phenomenon (<a class="graphic graphic_table graphicRef69467" href="/z/d/graphic/69467.html" rel="external">table 2</a>) [<a href="#rid49">49,50</a>]. Respiratory system involvement includes pleuritis (pleural effusions and pleurisy) and, less commonly, diffuse parenchymal lung disease. (See  <a class="medical medical_review" href="/z/d/html/4677.html" rel="external">"Drug-induced lupus"</a>.)</p><p></p><p class="bulletIndent1">Among patients with procainamide-induced lupus, pleuritis occurs in approximately half. While a high pleural fluid antinuclear antibody (ANA) may be seen in drug-induced lupus pleuritis, it lacks specificity and does not differentiate systemic lupus erythematosus (SLE) from drug-induced lupus. There are, however, a number of features that help to distinguish drug-induced lupus from SLE, including the general absence of renal and central nervous system disease with drug-induced lupus and the presence of anti-double stranded DNA antibodies and hypocomplementemia with SLE (<a class="graphic graphic_table graphicRef69467" href="/z/d/graphic/69467.html" rel="external">table 2</a>). The clinical manifestations and diagnosis of drug-induced lupus are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/4677.html" rel="external">"Drug-induced lupus", section on 'Diagnostic approach'</a> and  <a class="medical medical_review" href="/z/d/html/6698.html" rel="external">"Pleural fluid analysis in adults with a pleural effusion"</a>.)</p><p></p><p class="bulletIndent1">One sensitive serologic indicator of drug-induced lupus is the presence of antibodies directed against the histone complex H2A-H2B [<a href="#rid51">51</a>]; the absence of this autoantibody essentially rules out drug-induced lupus. However, approximately 60 to 80 percent of patients with active spontaneous SLE also have this antibody. Thus, the presence of anti-histone antibodies does not discriminate between idiopathic SLE and drug-induced lupus. (See  <a class="medical medical_review" href="/z/d/html/4677.html" rel="external">"Drug-induced lupus"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Antiphospholipid antibodies</strong> – Antiphospholipid antibodies are also associated with <a class="drug drug_general" data-topicid="9813" href="/z/d/drug information/9813.html" rel="external">procainamide</a>, although the antiphospholipid antibody syndrome due to procainamide is rare [<a href="#rid52">52,53</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Respiratory muscle weakness</strong> – <a class="drug drug_general" data-topicid="9813" href="/z/d/drug information/9813.html" rel="external">Procainamide</a> may rarely have adverse effects on respiratory muscles by several mechanisms [<a href="#rid54">54</a>]. First, it can competitively block the acetylcholine receptor, thereby impairing neuromuscular transmission and causing postoperative apnea and/or a myasthenia gravis-like syndrome. Hence, procainamide may induce a myasthenic crisis in patients with underlying autoimmune myasthenia gravis [<a href="#rid55">55</a>]. Second, myositis has also been reported in association with drug-induced lupus and can impair respiratory muscle function.</p><p></p><p class="headingAnchor" id="H13"><span class="h1">QUINIDINE</span><span class="headingEndMark"> — </span>The antiarrhythmic agent <a class="drug drug_general" data-topicid="9846" href="/z/d/drug information/9846.html" rel="external">quinidine</a> has been associated with drug-induced lupus, respiratory muscle weakness, acute pneumonitis, and diffuse alveolar hemorrhage (DAH) in case reports [<a href="#rid54">54,56,57</a>]. The incidence of drug-induced lupus is much lower than with <a class="drug drug_general" data-topicid="9813" href="/z/d/drug information/9813.html" rel="external">procainamide</a>, which may be explained by quinidine's lack of an amine group [<a href="#rid58">58</a>]. Similar to procainamide, the pulmonary manifestations associated with quinidine-induced lupus are primarily related to pleuritis [<a href="#rid58">58</a>]. (See <a class="local">'Drug-induced lupus'</a> above.)</p><p><a class="drug drug_general" data-topicid="9846" href="/z/d/drug information/9846.html" rel="external">Quinidine</a> can rarely cause a myasthenia gravis-like syndrome and has been shown to exacerbate autoimmune myasthenia gravis [<a href="#rid54">54</a>].</p><p>Two cases of DAH have been reported in patients with <a class="drug drug_general" data-topicid="9846" href="/z/d/drug information/9846.html" rel="external">quinidine</a> sulfate-induced thrombocytopenia [<a href="#rid56">56,59</a>].</p><p class="headingAnchor" id="H982217513"><span class="h1">STATINS</span><span class="headingEndMark"> — </span>Various statins have been associated with interstitial lung disease (fibrotic, eosinophilic, nonspecific) in case reports [<a href="#rid60">60-62</a>]. Onset of lung disease was 1 week to 10 years after initiation of statin therapy. Radiographic findings included ground glass, consolidative, and reticular opacities. While a case control study of patients with idiopathic pulmonary fibrosis (IPF) did not find an increased risk of IPF associated with statin use [<a href="#rid63">63</a>], this observation does not exclude the possibility of a drug-induced pneumonitis due to a statin medication. </p><p>Conversely, a post hoc analysis of 624 patients randomized to placebo in three trials of <a class="drug drug_general" data-topicid="88424" href="/z/d/drug information/88424.html" rel="external">pirfenidone</a> in the treatment of IPF suggest that statins may have a beneficial effect on clinical outcomes in IPF [<a href="#rid64">64</a>]. Similarly, a potential beneficial effect on clinical outcomes has been found for patients taking a statin in trials of <a class="drug drug_general" data-topicid="97640" href="/z/d/drug information/97640.html" rel="external">nintedanib</a> for IPF [<a href="#rid65">65</a>]. </p><p>A meta-analysis of randomized trials determining the clinical impact of statin therapy on patients with pulmonary hypertension secondary to lung diseases (group 3) suggested that statins might be safe and beneficial for patients with pulmonary arterial hypertension due to chronic lung diseases [<a href="#rid66">66,67</a>]. However, no prospective clinical trials have been performed to validate these findings.</p><p class="headingAnchor" id="H14"><span class="h1">TOCAINIDE</span><span class="headingEndMark"> — </span>The anti-arrhythmic agent tocainide (no longer sold in the United States, limited availability elsewhere) has uncommonly been associated with an interstitial pneumonitis that develops after a few months of therapy [<a href="#rid68">68-70</a>]. Computed tomography (CT) typically shows septal thickening and consolidative opacities [<a href="#rid69">69</a>]. The lung disease may be characterized initially by a neutrophilic alveolitis with organizing pneumonia; irreversible fibrosis may develop with continuing inflammation.</p><p>In most cases, symptoms remit with discontinuation of therapy. However, progressive respiratory failure has been described in patients with advanced fibrosis despite discontinuation of tocainide [<a href="#rid68">68</a>]. Systemic glucocorticoids may hasten recovery in more severe disease. </p><p class="headingAnchor" id="H27299493"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Overview</strong> – Several cardiovascular drugs can cause symptoms like dyspnea, cough, and radiographic abnormalities. However, diffuse parenchymal lung disease linked to these drugs is rare. Identified respiratory side effects include: upper airway angioedema or hematoma, bronchoconstriction, cough, interstitial pneumonitis, organizing pneumonia, eosinophilic pneumonia, drug-induced lupus, acute respiratory distress syndrome, diffuse alveolar hemorrhage, pleuritis, pleural effusion, and solitary lung mass (<a class="graphic graphic_table graphicRef54967 graphicRef69778" href="/z/d/graphic/54967.html" rel="external">table 1A-B</a>). (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Angiotensin-converting enzyme inhibitors</strong> – Angiotensin-converting enzyme (ACE) inhibitors are associated with cough, angioedema, and, rarely, pneumonitis. The cough is typically nonproductive, persistent, and often nocturnal (in 5 to 20 percent of patients) and frequently requires cessation of therapy. (See <a class="local">'Angiotensin-converting enzyme inhibitors'</a> above and  <a class="medical medical_review" href="/z/d/html/3816.html" rel="external">"Major side effects of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Antiplatelet agents, anticoagulants, and thrombolytics</strong> – Treatment of coronary artery disease with anti-platelet medications (glycoprotein IIB/IIIA antagonist), anticoagulants (vitamin K antagonists, direct thrombin inhibitor, factor Xa inhibitor), and thrombolytic agents has been associated with bland diffuse alveolar hemorrhage (DAH). Rare cases of upper airway obstruction due to retropharyngeal or glottic hematoma have been reported. <a class="drug drug_general" data-topicid="8921" href="/z/d/drug information/8921.html" rel="external">Clopidogrel</a> and <a class="drug drug_general" data-topicid="9996" href="/z/d/drug information/9996.html" rel="external">ticlopidine</a> have infrequently been associated with interstitial pneumonitis. (See <a class="local">'Antiplatelet (non-aspirin), anticoagulant, and thrombolytic medications'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">Aspirin</a> – Aspirin causes acute bronchoconstriction in patients with aspirin-exacerbated respiratory disease (triad of asthma, nasal polyps, acute bronchoconstriction due to aspirin). The dose of aspirin that provokes a reaction varies among patients; some patients are able to tolerate 81 mg, but develop symptoms at 162 or 325 mg. Aspirin desensitization, a protocol that may also help improve asthma symptoms, is an option for patients with AERD who require aspirin therapy. (See <a class="local">'Aspirin'</a> above and  <a class="medical medical_review" href="/z/d/html/520.html" rel="external">"Aspirin-exacerbated respiratory disease"</a> and  <a class="medical medical_review" href="/z/d/html/15539.html" rel="external">"Aspirin-exacerbated respiratory disease: NSAID challenge and desensitization"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Beta-adrenergic receptor blockers</strong> – Nonselective beta1/beta2 blockers (eg, <a class="drug drug_general" data-topicid="9829" href="/z/d/drug information/9829.html" rel="external">propranolol</a>) can cause bronchoconstriction in susceptible individuals, but this effect is substantially less likely to occur with selective beta1 blockers (eg, <a class="drug drug_general" data-topicid="8940" href="/z/d/drug information/8940.html" rel="external">atenolol</a>, <a class="drug drug_general" data-topicid="9645" href="/z/d/drug information/9645.html" rel="external">metoprolol</a>). (See <a class="local">'Beta-adrenergic receptor blockers'</a> above and  <a class="medical medical_review" href="/z/d/html/1437.html" rel="external">"Management of the patient with COPD and cardiovascular disease"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cardiovascular drugs associated with interstitial pneumonias</strong> – Eosinophilic pneumonitis has rarely been found in patients taking ACE inhibitors, beta-blocker medications, and statins. Organizing pneumonia has been reported in association with <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">amiodarone</a>, beta-blocker medications, and tocainide. Statins, paclitaxel-eluting stents, and tocainide have been associated with pneumonitis in case reports. (See <a class="local">'Amiodarone'</a> above and <a class="local">'Angiotensin-converting enzyme inhibitors'</a> above and <a class="local">'Beta-adrenergic receptor blockers'</a> above and <a class="local">'Statins'</a> above and <a class="local">'Tocainide'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Drug-induced lupus</strong> – Drug-induced lupus has been reported with beta-blocker medications, <a class="drug drug_general" data-topicid="8528" href="/z/d/drug information/8528.html" rel="external">hydralazine</a>, <a class="drug drug_general" data-topicid="9813" href="/z/d/drug information/9813.html" rel="external">procainamide</a>, and <a class="drug drug_general" data-topicid="9846" href="/z/d/drug information/9846.html" rel="external">quinidine</a>. The diagnosis of drug-induced lupus is based on the combination of clinical manifestations (eg, pleuropericarditis), serologic evaluation, and response to discontinuation of the implicated medication. Features that help to differentiate drug-induced lupus from systemic lupus erythematosus (SLE) are listed in the table (<a class="graphic graphic_table graphicRef69467" href="/z/d/graphic/69467.html" rel="external">table 2</a>). The presence of anti-histone antibodies in the absence of other autoantibodies (eg, anti-double stranded DNA, anti-ribonucleoprotein, anti-Smith) strongly favors drug-induced lupus. (See <a class="local">'Drug-induced lupus'</a> above and <a class="local">'Hydralazine'</a> above and <a class="local">'Procainamide'</a> above and <a class="local">'Quinidine'</a> above and  <a class="medical medical_review" href="/z/d/html/4677.html" rel="external">"Drug-induced lupus"</a>.)</p><p></p><p class="bulletIndent1">Although respiratory muscle weakness may arise from drug-induced lupus (<a class="graphic graphic_table graphicRef69467" href="/z/d/graphic/69467.html" rel="external">table 2</a>), <a class="drug drug_general" data-topicid="9813" href="/z/d/drug information/9813.html" rel="external">procainamide</a> and <a class="drug drug_general" data-topicid="9846" href="/z/d/drug information/9846.html" rel="external">quinidine</a> can also cause respiratory muscle weakness by unmasking or exacerbating underlying myasthenia gravis. (See <a class="local">'Procainamide'</a> above and <a class="local">'Quinidine'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Dicpinigaitis PV. Angiotensin-converting enzyme inhibitor-induced cough: ACCP evidence-based clinical practice guidelines. Chest 2006; 129:169S.</a></li><li><a class="nounderline abstract_t">Benard A, Melloni B, Gosselin B, et al. Perindopril-associated pneumonitis. Eur Respir J 1996; 9:1314.</a></li><li><a class="nounderline abstract_t">Kidney JC, O'Halloran DJ, FitzGerald MX. Captopril and lymphocytic alveolitis. BMJ 1989; 299:981.</a></li><li><a class="nounderline abstract_t">Schatz PL, Mesologites D, Hyun J, et al. Captopril-induced hypersensitivity lung disease. An immune-complex-mediated phenomenon. Chest 1989; 95:685.</a></li><li><a class="nounderline abstract_t">Slesnick TC, Mott AR, Fraser CD Jr, Chang AC. Captopril-induced pulmonary infiltrates with eosinophilia in an infant with congenital heart disease. Pediatr Cardiol 2005; 26:690.</a></li><li><a class="nounderline abstract_t">Watanabe K, Nishimura K, Shiode M, et al. Captopril, an angiotensin-converting enzyme inhibitor, induced pulmonary infiltration with eosinophilia. Intern Med 1996; 35:142.</a></li><li><a class="nounderline abstract_t">Caldeira D, David C, Sampaio C. Tolerability of angiotensin-receptor blockers in patients with intolerance to angiotensin-converting enzyme inhibitors: a systematic review and meta-analysis. Am J Cardiovasc Drugs 2012; 12:263.</a></li><li><a class="nounderline abstract_t">Kilaru PK, Schweiger MJ, Kozman HA, Weil TR. Diffuse alveolar hemorrhage after clopidogrel use. J Invasive Cardiol 2001; 13:535.</a></li><li><a class="nounderline abstract_t">Conley M, Patino G, Romick B, et al. Abciximab-induced alveolar hemorrhage after percutaneous coronary intervention. Can J Cardiol 2008; 24:149.</a></li><li><a class="nounderline abstract_t">Mikkilineni H, Bruhl SR, Colyer WR, Pandya U. A retrospective analysis and case series of glycoprotein IIb/IIIa inhibitor associated diffuse alveolar hemorrhage: two case reports. Cases J 2009; 2:8553.</a></li><li><a class="nounderline abstract_t">Hanf W, Duntze J, Hida H, et al. [The implication of a direct antithrombine in the appearance of (serious) postoperative acute respiratory distress]. Ann Fr Anesth Reanim 2009; 28:885.</a></li><li><a class="nounderline abstract_t">Kim Y, Lim J, Lim J, et al. Pulmonary Alveolar Hemorrhage after Clopidogrel Use for ST Elevation Myocardial Infarction. Korean Circ J 2013; 43:497.</a></li><li><a class="nounderline abstract_t">Ikeda M, Tanaka H, Sadamatsu K. Diffuse alveolar hemorrhage as a complication of dual antiplatelet therapy for acute coronary syndrome. Cardiovasc Revasc Med 2011; 12:407.</a></li><li><a class="nounderline abstract_t">Guo J, Xu M, Xi Y. Tirofiban-induced diffuse alveolar hemorrhage: after primary angioplasty. Tex Heart Inst J 2012; 39:99.</a></li><li><a class="nounderline abstract_t">Gill DS, Ng K, Ng KS. Massive pulmonary haemorrhage complicating the treatment of acute coronary syndrome. Heart 2004; 90:e15.</a></li><li><a class="nounderline abstract_t">Kalra S, Bell MR, Rihal CS. Alveolar hemorrhage as a complication of treatment with abciximab. Chest 2001; 120:126.</a></li><li><a class="nounderline abstract_t">Iskandar SB, Kasasbeh ES, Mechleb BK, et al. Alveolar hemorrhage: an underdiagnosed complication of treatment with glycoprotein IIb/IIIa inhibitors. J Interv Cardiol 2006; 19:356.</a></li><li><a class="nounderline abstract_t">Waness A, Aldabbagh T, Harakati M. Diffuse alveolar haemorrhage secondary to warfarin therapy for atrial fibrillation: a case report and literature review. BMJ Case Rep 2009; 2009.</a></li><li><a class="nounderline abstract_t">Uysal E, Çevik E, Solak S, et al. A life-threatening complication of warfarin therapy in ED: diffuse alveolar hemorrhage. Am J Emerg Med 2014; 32:690.e3.</a></li><li><a class="nounderline abstract_t">Erdogan D, Kocaman O, Oflaz H, Goren T. Alveolar hemorrhage associated with warfarin therapy: a case report and literature review. Int J Cardiovasc Imaging 2004; 20:155.</a></li><li><a class="nounderline abstract_t">Ozawa T, Terai H, Kajino A, et al. Apixaban-Associated Diffuse Alveolar Hemorrhage in an Elderly Man with Multiple Complications. Am J Case Rep 2022; 23:e937809.</a></li><li><a class="nounderline abstract_t">Gabrilovich MI, Buxton DE, Lykins DM, et al. Diffuse alveolar hemorrhage secondary to apixaban administration. Chest 2014; 146:e115.</a></li><li><a class="nounderline abstract_t">Awadh N, Ronco JJ, Bernstein V, et al. Spontaneous pulmonary hemorrhage after thrombolytic therapy for acute myocardial infarction. Chest 1994; 106:1622.</a></li><li><a class="nounderline abstract_t">Masip J, Vecilla F, Páez J. Diffuse pulmonary hemorrhage after fibrinolytic therapy for acute myocardial infarction. Int J Cardiol 1998; 63:95.</a></li><li><a class="nounderline abstract_t">Ayyub M, Barlas S, Iqbal M, Khurshid SM. Diffuse alveolar hemorrhages and hemorrhagic pleural effusion after thrombolytic therapy with streptokinase for acute myocardial infarction. Saudi Med J 2003; 24:217.</a></li><li><a class="nounderline abstract_t">Akoğlu E, Seyfeli E, Akoğlu S, et al. Retropharyngeal hematoma as a complication of anticoagulation therapy. Ear Nose Throat J 2008; 87:156.</a></li><li><a class="nounderline abstract_t">Sinert R, Scalea T. Retropharyngeal and bowel hematomas in an anticoagulated patient. Acad Emerg Med 1994; 1:67.</a></li><li><a class="nounderline abstract_t">Chiti-Batelli S, Vaz F, Coman S. Traumatic retropharyngeal haematoma in an anticoagulated patient: Case report and proposal for a clinical protocol. Acta Otolaryngol 2005; 125:443.</a></li><li><a class="nounderline abstract_t">Persoz CF, Cornella F, Kaeser P, Rochat T. Ticlopidine-induced interstitial pulmonary disease: a case report. Chest 2001; 119:1963.</a></li><li><a class="nounderline abstract_t">Nakamura R, Imamura T, Onitsuka H, et al. Interstitial pneumonia induced by ticlopidine. Circ J 2002; 66:773.</a></li><li><a class="nounderline abstract_t">Tamagaki G, Matsushita H, Suzumura T, et al. [A case of drug-induced pneumonia caused by clopidogrel]. Nihon Kokyuki Gakkai Zasshi 2010; 48:404.</a></li><li><a class="nounderline abstract_t">Mizuno Y, Shimizu H, Yamashita M, et al. [A case of clopidogrel-induced eosinophilic pneumonia]. Nihon Kokyuki Gakkai Zasshi 2011; 49:838.</a></li><li><a class="nounderline abstract_t">Berges-Gimeno MP, Simon RA, Stevenson DD. Long-term treatment with aspirin desensitization in asthmatic patients with aspirin-exacerbated respiratory disease. J Allergy Clin Immunol 2003; 111:180.</a></li><li><a class="nounderline abstract_t">McGavin CR, Williams IP. The effects of oral propranolol and metoprolol on lung function and exercise performance in chronic airways obstruction. Br J Dis Chest 1978; 72:327.</a></li><li><a class="nounderline abstract_t">Salpeter S, Ormiston T, Salpeter E. Cardioselective beta-blockers for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2005; :CD003566.</a></li><li><a class="nounderline abstract_t">Provencher S, Herve P, Jais X, et al. Deleterious effects of beta-blockers on exercise capacity and hemodynamics in patients with portopulmonary hypertension. Gastroenterology 2006; 130:120.</a></li><li><a class="nounderline abstract_t">Horvatits T, Fuhrmann V. Therapeutic options in pulmonary hepatic vascular diseases. Expert Rev Clin Pharmacol 2014; 7:31.</a></li><li><a class="nounderline abstract_t">Cody RJ Jr, Calabrese LH, Clough JD, et al. Development of antinuclear antibodies during acebutolol therapy. Clin Pharmacol Ther 1979; 25:800.</a></li><li><a class="nounderline abstract_t">Record NB Jr. Acebutolol-induced pleuropulmonary lupus syndrome. Ann Intern Med 1981; 95:326.</a></li><li><a class="nounderline abstract_t">Faller M, Quoix E, Popin E, et al. Migratory pulmonary infiltrates in a patient treated with sotalol. Eur Respir J 1997; 10:2159.</a></li><li><a class="nounderline abstract_t">Camus P, Lombard JN, Perrichon M, et al. Bronchiolitis obliterans organising pneumonia in patients taking acebutolol or amiodarone. Thorax 1989; 44:711.</a></li><li><a class="nounderline abstract_t">Markou N, Antzoulatos N, Haniotou A, et al. A case of drug-induced pneumonitis caused by carvedilol. Respiration 2004; 71:650.</a></li><li><a class="nounderline abstract_t">Espinosa MC, Ding B, Choi K, et al. A simultaneous presentation of drug-induced lupus with drug-induced ANCA vasculitis secondary to hydralazine use in a patient with sarcoidosis. Proc (Bayl Univ Med Cent) 2019; 32:231.</a></li><li><a class="nounderline abstract_t">Webb DB, Whale RJ. Pleuropericardial effusion associated with minoxidil administration. Postgrad Med J 1982; 58:319.</a></li><li><a class="nounderline abstract_t">Siddiqui A, Ansari M, Shakil J, Chemitiganti R. Minoxidil-associated exudative pleural effusion. South Med J 2010; 103:458.</a></li><li><a class="nounderline abstract_t">Chan ED, Chan MM, Chan MM. Pulse oximetry: understanding its basic principles facilitates appreciation of its limitations. Respir Med 2013; 107:789.</a></li><li><a class="nounderline abstract_t">Kato K, Fukuda S, Fujimaki T, et al. Paclitaxel-induced interstitial pneumonia after drug-eluting stent implantation: report of a fatal case. Intern Med 2009; 48:911.</a></li><li><a class="nounderline abstract_t">Fujimaki T, Kato K, Fukuda S, et al. Acute interstitial pneumonitis after implantation of paclitaxel-eluting stents: a report of two fatal cases. Int J Cardiol 2011; 148:e21.</a></li><li><a class="nounderline abstract_t">Zitnik, RJ. Drug-induced lung disease: Antiarrhythmic agents. J Respir Dis 1996; 17:254.</a></li><li><a class="nounderline abstract_t">Arnaud L, Mertz P, Gavand PE, et al. Drug-induced systemic lupus: revisiting the ever-changing spectrum of the disease using the WHO pharmacovigilance database. Ann Rheum Dis 2019; 78:504.</a></li><li><a class="nounderline abstract_t">Totoritis MC, Tan EM, McNally EM, Rubin RL. Association of antibody to histone complex H2A-H2B with symptomatic procainamide-induced lupus. N Engl J Med 1988; 318:1431.</a></li><li><a class="nounderline abstract_t">Merrill JT, Shen C, Gugnani M, et al. High prevalence of antiphospholipid antibodies in patients taking procainamide. J Rheumatol 1997; 24:1083.</a></li><li><a class="nounderline abstract_t">Asherson RA, Zulman J, Hughes GR. Pulmonary thromboembolism associated with procainamide induced lupus syndrome and anticardiolipin antibodies. Ann Rheum Dis 1989; 48:232.</a></li><li><a class="nounderline abstract_t">Aldrich TK, Prezant DJ. Adverse effects of drugs on the respiratory muscles. Clin Chest Med 1990; 11:177.</a></li><li><a class="nounderline abstract_t">Godley PJ, Morton TA, Karboski JA, Tami JA. Procainamide-induced myasthenic crisis. Ther Drug Monit 1990; 12:411.</a></li><li><a class="nounderline abstract_t">Alperin JB, deGroot WJ, Cimo PL. Quinidine-induced thrombocytopenia with pulmonary hemorrhage. Arch Intern Med 1980; 140:266.</a></li><li><a class="nounderline abstract_t">Poukkula A, Pääkkö P. Quinidine-induced reversible pneumonitis. Chest 1994; 106:304.</a></li><li><a class="nounderline abstract_t">McCormack GD, Barth WF. Quinidine induced lupus syndrome. Semin Arthritis Rheum 1985; 15:73.</a></li><li><a class="nounderline abstract_t">LeBlanc KE. A second case of quinidine-induced thrombocytopenia with pulmonary hemorrhage. Arch Intern Med 1980; 140:1250.</a></li><li><a class="nounderline abstract_t">Fernández AB, Karas RH, Alsheikh-Ali AA, Thompson PD. Statins and interstitial lung disease: a systematic review of the literature and of food and drug administration adverse event reports. Chest 2008; 134:824.</a></li><li><a class="nounderline abstract_t">Liebhaber MI, Wright RS, Gelberg HJ, et al. Polymyalgia, hypersensitivity pneumonitis and other reactions in patients receiving HMG-CoA reductase inhibitors: a report of ten cases. Chest 1999; 115:886.</a></li><li><a class="nounderline abstract_t">Liscoët-Loheac N, André N, Couturaud F, et al. [Hypersensitivity pneumonitis in a patient taking pravastatin]. Rev Mal Respir 2001; 18:426.</a></li><li><a class="nounderline abstract_t">Ponnuswamy A, Manikandan R, Sabetpour A, et al. Association between ischaemic heart disease and interstitial lung disease: a case-control study. Respir Med 2009; 103:503.</a></li><li><a class="nounderline abstract_t">Kreuter M, Bonella F, Maher TM, et al. Effect of statins on disease-related outcomes in patients with idiopathic pulmonary fibrosis. Thorax 2017; 72:148.</a></li><li><a class="nounderline abstract_t">Kreuter M, Costabel U, Richeldi L, et al. Statin Therapy and Outcomes in Trials of Nintedanib in Idiopathic Pulmonary Fibrosis. Respiration 2018; 95:317.</a></li><li><a class="nounderline abstract_t">Zhang MZ, Qian DH, Xu JC, et al. Statins may be beneficial for patients with pulmonary hypertension secondary to lung diseases. J Thorac Dis 2017; 9:2437.</a></li><li><a class="nounderline abstract_t">Faraj R, Paine D, Black SM, Wang T. Anti-inflammatory Effects of Statins in Lung Vascular Pathology: From Basic Science to Clinical Trials. Adv Exp Med Biol 2021; 1303:33.</a></li><li><a class="nounderline abstract_t">Feinberg L, Travis WD, Ferrans V, et al. Pulmonary fibrosis associated with tocainide: report of a case with literature review. Am Rev Respir Dis 1990; 141:505.</a></li><li><a class="nounderline abstract_t">Stein MG, Demarco T, Gamsu G, et al. Computed tomography: pathologic correlation in lung disease due to tocainide. Am Rev Respir Dis 1988; 137:458.</a></li><li><a class="nounderline abstract_t">Van Natta B, Lazarus M, Li C. Irreversible interstitial pneumonitis associated with tocainide therapy. West J Med 1988; 149:91.</a></li></ol></div><div id="topicVersionRevision">Topic 4345 Version 24.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16428706" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Angiotensin-converting enzyme inhibitor-induced cough: ACCP evidence-based clinical practice guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8804953" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Perindopril-associated pneumonitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2508967" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Captopril and lymphocytic alveolitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2522035" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Captopril-induced hypersensitivity lung disease. An immune-complex-mediated phenomenon.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16132305" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Captopril-induced pulmonary infiltrates with eosinophilia in an infant with congenital heart disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8680103" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Captopril, an angiotensin-converting enzyme inhibitor, induced pulmonary infiltration with eosinophilia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22587776" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Tolerability of angiotensin-receptor blockers in patients with intolerance to angiotensin-converting enzyme inhibitors: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11435642" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Diffuse alveolar hemorrhage after clopidogrel use.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18273491" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Abciximab-induced alveolar hemorrhage after percutaneous coronary intervention.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19830082" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : A retrospective analysis and case series of glycoprotein IIb/IIIa inhibitor associated diffuse alveolar hemorrhage: two case reports.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19837548" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : [The implication of a direct antithrombine in the appearance of (serious) postoperative acute respiratory distress].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23964298" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Pulmonary Alveolar Hemorrhage after Clopidogrel Use for ST Elevation Myocardial Infarction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21514251" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Diffuse alveolar hemorrhage as a complication of dual antiplatelet therapy for acute coronary syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22412240" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Tirofiban-induced diffuse alveolar hemorrhage: after primary angioplasty.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14966076" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Massive pulmonary haemorrhage complicating the treatment of acute coronary syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11451827" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Alveolar hemorrhage as a complication of treatment with abciximab.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16881986" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Alveolar hemorrhage: an underdiagnosed complication of treatment with glycoprotein IIb/IIIa inhibitors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21686645" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Diffuse alveolar haemorrhage secondary to warfarin therapy for atrial fibrillation: a case report and literature review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24412020" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : A life-threatening complication of warfarin therapy in ED: diffuse alveolar hemorrhage.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15068147" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Alveolar hemorrhage associated with warfarin therapy: a case report and literature review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36345226" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Apixaban-Associated Diffuse Alveolar Hemorrhage in an Elderly Man with Multiple Complications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25180742" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Diffuse alveolar hemorrhage secondary to apixaban administration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7956438" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Spontaneous pulmonary hemorrhage after thrombolytic therapy for acute myocardial infarction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9482153" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Diffuse pulmonary hemorrhage after fibrinolytic therapy for acute myocardial infarction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12682693" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Diffuse alveolar hemorrhages and hemorrhagic pleural effusion after thrombolytic therapy with streptokinase for acute myocardial infarction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18404913" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Retropharyngeal hematoma as a complication of anticoagulation therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7621156" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Retropharyngeal and bowel hematomas in an anticoagulated patient.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15823820" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Traumatic retropharyngeal haematoma in an anticoagulated patient: Case report and proposal for a clinical protocol.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11399735" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Ticlopidine-induced interstitial pulmonary disease: a case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12197605" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Interstitial pneumonia induced by ticlopidine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20560445" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : [A case of drug-induced pneumonia caused by clopidogrel].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22171488" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : [A case of clopidogrel-induced eosinophilic pneumonia].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12532116" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Long-term treatment with aspirin desensitization in asthmatic patients with aspirin-exacerbated respiratory disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/365214" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : The effects of oral propranolol and metoprolol on lung function and exercise performance in chronic airways obstruction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16235327" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Cardioselective beta-blockers for chronic obstructive pulmonary disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16401475" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Deleterious effects of beta-blockers on exercise capacity and hemodynamics in patients with portopulmonary hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24308785" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Therapeutic options in pulmonary hepatic vascular diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/87291" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Development of antinuclear antibodies during acebutolol therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6973944" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Acebutolol-induced pleuropulmonary lupus syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9311519" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Migratory pulmonary infiltrates in a patient treated with sotalol.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2588206" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Bronchiolitis obliterans organising pneumonia in patients taking acebutolol or amiodarone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15627880" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : A case of drug-induced pneumonitis caused by carvedilol.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31191136" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : A simultaneous presentation of drug-induced lupus with drug-induced ANCA vasculitis secondary to hydralazine use in a patient with sarcoidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7111124" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Pleuropericardial effusion associated with minoxidil administration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20375958" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Minoxidil-associated exudative pleural effusion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23490227" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Pulse oximetry: understanding its basic principles facilitates appreciation of its limitations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19483360" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Paclitaxel-induced interstitial pneumonia after drug-eluting stent implantation: report of a fatal case.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19239975" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Acute interstitial pneumonitis after implantation of paclitaxel-eluting stents: a report of two fatal cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Drug-induced lung disease: Antiarrhythmic agents</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30793701" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Drug-induced systemic lupus: revisiting the ever-changing spectrum of the disease using the WHO pharmacovigilance database.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3259287" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Association of antibody to histone complex H2A-H2B with symptomatic procainamide-induced lupus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9195513" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : High prevalence of antiphospholipid antibodies in patients taking procainamide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2494958" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Pulmonary thromboembolism associated with procainamide induced lupus syndrome and anticardiolipin antibodies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2182277" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Adverse effects of drugs on the respiratory muscles.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2396315" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Procainamide-induced myasthenic crisis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7352824" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Quinidine-induced thrombocytopenia with pulmonary hemorrhage.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8020298" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Quinidine-induced reversible pneumonitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4035371" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Quinidine induced lupus syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7406627" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : A second case of quinidine-induced thrombocytopenia with pulmonary hemorrhage.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18689579" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Statins and interstitial lung disease: a systematic review of the literature and of food and drug administration adverse event reports.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10084510" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Polymyalgia, hypersensitivity pneumonitis and other reactions in patients receiving HMG-CoA reductase inhibitors: a report of ten cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11547251" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : [Hypersensitivity pneumonitis in a patient taking pravastatin].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19196502" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Association between ischaemic heart disease and interstitial lung disease: a case-control study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27708114" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Effect of statins on disease-related outcomes in patients with idiopathic pulmonary fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29414827" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Statin Therapy and Outcomes in Trials of Nintedanib in Idiopathic Pulmonary Fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28932549" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Statins may be beneficial for patients with pulmonary hypertension secondary to lung diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33788186" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Anti-inflammatory Effects of Statins in Lung Vascular Pathology: From Basic Science to Clinical Trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2137316" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Pulmonary fibrosis associated with tocainide: report of a case with literature review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3124678" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Computed tomography: pathologic correlation in lung disease due to tocainide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3136588" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Irreversible interstitial pneumonitis associated with tocainide therapy.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
